Inhibin as a diagnostic marker for ovarian cancer

Robertson, David; Pruysers, Enid; Jobling, Tom

doi:10.1016/j.canlet.2006.12.017

Cited by 47 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At presentation the tumor size varies considerably, from less than 5 to over 10 cm in diameter. Measurement of serum anti-mü llerian hormone (AMH) (also known as mü llerian inhibiting substance) levels, together with inhibin ␣ and estradiol, has proven to be helpful markers in the prognosis and follow-up of GCT patients (1,2,5,6). Low expression of AMH in the tumor associates with larger size, suggesting that the loss of AMH expression favors GCT growth (4).…”

mentioning

confidence: 99%

GATA-4 Regulates Bcl-2 Expression in Ovarian Granulosa Cell Tumors

et al. 2008

View full text Add to dashboard Cite

Excessive cell proliferation and decreased apoptosis have been implicated in the pathogenesis of ovarian granulosa cell tumors (GCTs). We hypothesized that transcription factor GATA-4 controls expression of the antiapoptotic factor Bcl-2 and the cell cycle regulator cyclin D2 in normal and neoplastic granulosa cells. To test this hypothesis, a tissue microarray based on 80 GCTs was subjected to immunohistochemistry for GATA-4, Bcl-2, and cyclin D2, and the data were correlated to clinical and histopathological parameters. In addition, quantitative RT-PCR for GATA-4, Bcl-2, and cyclin D2 was performed on 21 human GCTs. A mouse GCT model was used to complement these studies. The role of GATA-4 in the regulation of Bcl2 and ccdn2 (coding for cyclin D2) was studied by transactivation assays, and by disrupting GATA-4 function with dominant negative approaches in mouse and human GCT cell lines. We found that GATA-4 expression correlated with Bcl-2 and cyclin D2 expression in human and murine GCTs. Moreover, GATA-4 enhanced Bcl-2 and cyclin D2 promoter activity in murine GCT cells. Whereas GATA-4 overexpression up-regulated and dominant negative GATA-4 suppressed Bcl-2 expression in human GCT cells, the effects on cyclin D2 were negligible. Our results reveal a previously unknown relationship between GATA-4 and Bcl-2 in mammalian granulosa cells and GCTs, and suggest that GATA-4 influences granulosa cell fate by transactivating Bcl-2. (Endocrinology 149: 5635-5642, 2008)

show abstract

mentioning

confidence: 99%

GATA-4 Regulates Bcl-2 Expression in Ovarian Granulosa Cell Tumors

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Inhibins and activins have been demonstrated in normal and neoplastic tissue (Risbridger et al 2001), including breast cancer (Mylonas et al 2005a;Reis et al 2004), ovarian cancer (Robertson et al 2007;Zheng et al 1998), normal and pathological placental tissue Mylonas et al 2006b;Mylonas et al 2006c;Mylonas et al 2007) as well as normal and pathological endometrial tissue (Mylonas et al 2004;Mylonas et al 2005b;Mylonas et al 2006a;Mylonas et al 2009b;Worbs et al 2007). These members of the TGFb-familiy have been implicated in several important functions including in stem cell biology (Beattie et al 2005), reproductive biology (de Kretser et al 2002), systemic inflammation (Phillips et al 2009), carcinogenesis (Risbridger et al 2004), tumour suppressor activity (Matzuk et al 1992) and apoptosis (Chen et al 2002).…”

Section: Discussionmentioning

confidence: 95%

“…Although endometrial, prostate and ovarian cancers express these subunits (Mylonas et al 2006a;Risbridger et al 2001;Robertson et al 2007;Worbs et al 2007;Zheng et al 1998), it is quite unclear if and to what extent squamous epithelial cancers also synthesise these novel subunit. While inhibin A, inhibin B and activin A were detected in normal and neoplastic human uterine tissues, including cervical cancer (Petraglia et al 1998), it is still unclear if normal or cancerous cervical epithelial cells as well as cervical cancer cell lines can synthesise the novel inhibin-bE subunit.…”

Section: Introductionmentioning

confidence: 99%

Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines

et al. 2009

View full text Add to dashboard Cite

Inhibins are dimeric glycoproteins, composed of an alpha-subunit and one of two possible beta-subunits (betaA or betaB), with substantial roles in human reproduction and in endocrine-responsive tumours. Recently a novel beta subunit named betaE was described, although it is still unclear if normal or cancerous cervical epithelial cells as well as cervical cancer cell lines can synthesise the novel inhibin-betaE subunit. About 4 normal cervical tissue samples together with 10 specimens of well-differentiated squamous cervical cancer and adenocarcinoma of the cervix were immunohistochemical analyzed. Additionally, two cervical carcinoma cell lines (HeLa and CaSki) were analyzed by immunofluorescence and RT-PCR for the expression of this novel subunit. We demonstrated for the first time an immunolabelling of the inhibin-betaE subunit in normal and malignant cervical tissue, as well as cervical cancer cells. Although the physiological role is still quite unclear in cervical tissue, inhibin-betaE might play important roles in carcinogenesis. Moreover, the synthesis of this subunit in cervical carcinoma cell lines of squamous and glandular epithelial origins also allows the use of these cell lines in elucidating its functions in cervical cancer pathogenesis. However, since the expression of the inhibin-betaE is minimal in HeLa cells as assessed by immunofluorescence and RT-PCR, the CaSki cell line might be a better model for further functional experiments regarding cervical cancer pathogenesis.

show abstract

“…16 Inhibin is the better marker for granulosa cell tumour and mucinous epithelial carcinoma subtype, while CA125 is much better at detecting the serous and endometrioid subtypes of epithelial carcinoma. The two markers together detect more cases of ovarian cancer than each separately, with improved sensitivity and specificity.…”

Section: Discussionmentioning

confidence: 99%

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Dubbewar¹,

Pathak²,

Biswas³

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Ovarian cancers are diagnosed at an advanced stage. Early diagnosis is the key to reduce death from ovarian cancer. The present study is an effort to assess the suitability of combined test using CA 125 and Inhibin for early diagnosis of ovarian cancer as compared to CA125 or Inhibin alone.Methods: Fifty women with clinical suspicion of ovarian malignancy attending Gynae OPD were enrolled. All of these women were subjected to estimation of CA 125 and Inhibin levels prior to surgical intervention. A value of 35 IU/ml was taken as positive for CA 125. For Inhibin, 10.5 pg/ml was taken as cut off for premenopausal patients, whereas, any detectable assays were taken as positive for postmenopausal patients. The results were analyzed after establishing final histopathology of the disease.Results: Out of 50 patients recruited, 30 (60%) were found to have carcinoma ovary and 20 (40%) were found to have benign diseases. Out of 30 cases of carcinoma ovary, CA125 was raised in 81% of cases and Inhibin was raised in 78% of cases. For detection of carcinoma ovary, CA 125 was found to have a sensitivity of 90% and specificity of 60% with a positive predictive value of 77% and negative predictive value of 80% which were statistically significant. Sensitivity and specificity of serum Inhibin for the same was 86.6% and 20% respectively. The positive and negative predictive value were 61.9% and 50%, which were not statistically significant. Sensitivity and specificity of combined CA125 and Inhibin were 100% and 30% respectively. The positive and negative predictive value were 68.1% and 100% respectively, which were statistically significant.Conclusions: Combined use of CA125 and Inhibin has got better sensitivity and specificity in detection of ovarian cancer in comparison to CA 125 or Inhibin used alone.

show abstract

Inhibin as a diagnostic marker for ovarian cancer

Cited by 47 publications

References 23 publications

GATA-4 Regulates Bcl-2 Expression in Ovarian Granulosa Cell Tumors

GATA-4 Regulates Bcl-2 Expression in Ovarian Granulosa Cell Tumors

Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Contact Info

Product

Resources

About